Zobrazeno 1 - 3
of 3
pro vyhledávání: '"James Vanhie"'
Autor:
James Vanhie, Ricardo Fernandes, Eric Winquist, Anupam Batra, Nicholas Power, Scott Ernst, Kylea R. Potvin
Introduction Intensified chemotherapy improved outcomes for men with poor-prognosis metastatic germ cell cancer (GCC) and unfavorable tumor marker decline after one cycle of bleomycin, etoposide, and cisplatin (BEP) chemotherapy in the GETUG-13 trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff890eedb025a9771440913960e5e949
https://europepmc.org/articles/PMC7012285/
https://europepmc.org/articles/PMC7012285/
Introduction: Post-chemotherapy residual masses (PCRMs) may contain persistent cancer or teratoma in more than 50% of patients with metastatic non-seminomatous germ cell tumours (mNSGCTs). Retroperitoneal lymph node dissection (RPLND) is curative, bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8c514f0dee0ba9beda7ce21599e7d39
https://europepmc.org/articles/PMC5110407/
https://europepmc.org/articles/PMC5110407/
Autor:
Nedal Bukhari, Andrea Marie Ibrahim, Lori Sax, Michael M. Vickers, Christina Canil, Sandeep Sehdev, Kim Koczka, Kylea Potvin, Michael Ong, D. Scott Ernst, M. Neil Reaume, Eric Winquist, James Vanhie
Publikováno v:
Journal of Clinical Oncology. 36:193-193
193 Background: Outcomes of patients (pts) undergoing CHT for mHSPC are heterogeneous, with some rapidly developing castration-resistance (CRPC). While AVPC ("anaplastic") features are described in CRPC, less is known in the mHSPC setting. In this mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a2d8827f4644f188978bcab8620ecbb
https://doi.org/10.1200/jco.2018.36.6_suppl.193
https://doi.org/10.1200/jco.2018.36.6_suppl.193
